Enamine's IDD Platform Accelerates Nuclide Therapeutics' Precision Radiotheranostics Pipeline Towards the Clinic
Nuclide Therapeutics Leverages Enamine's Deep Expertise in Rapid and Scalable Synthesis of Small Molecules
KYIV, UKRAINE, April 2, 2026 /EINPresswire.com/ -- Nuclide Therapeutics and Enamine initiated their cooperation in 2025. Since then, Enamine has supported Nuclide Therapeutics in progressing from preclinical evaluation towards IND-enabling studies and first-in-human clinical trials for its lead program focused on first-in-class molecular radiotherapies for therapy-resistant cancers. The relationship proved to be highly productive and innovative, delivering development milestones ahead of schedule with short development cycles and efficient use of resources.
Nuclide Therapeutics is committed to advancing a new generation of precision radiotheranostics specifically designed to overcome resistance to current cancer therapies. The collaboration between the two companies has enabled to accelerate key aspects of Nuclide Therapeuticsโ preclinical development through Enamine`s strong expertise in synthetic chemistry. Enamine`s ability to deliver high-quality materials within compressed timelines has been instrumental in supporting Nuclide Therapeutics' radiochemistry activities and progressing their program towards IND-enabling studies and first-in-human evaluation.
Enamineโs deep understanding of chemical space is reflected in its REAL Space, the worldโs largest and most trusted collection of make-on-demand small molecules, capturing a significant share of synthetically accessible chemical space. REAL Compounds are readily synthesised through validated parallel synthesis protocols using qualified in stock building blocks.
In combination with its integrated capabilities in medicinal chemistry, synthetic chemistry, route scouting, and scale-up, alongside optimized R&D logistics, Enamine enables rapid design-make-test-analyse (DMTA) cycles and efficient production of small molecules within short timelines. Enamine Germany, based in Frankfurt, provides strong support in project coordination, rapid development, and scale-up activities.
๐๐ข๐๐ก๐๐ซ๐ ๐๐๐ฐ๐๐ซ๐๐ฌ, ๐๐จ-๐ ๐จ๐ฎ๐ง๐๐๐ซ & ๐๐๐ ๐จ๐ ๐๐ฎ๐๐ฅ๐ข๐๐ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ: "๐๐ถ๐ณ ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ช๐ฆ๐ฏ๐ค๐ฆ ๐ธ๐ฐ๐ณ๐ฌ๐ช๐ฏ๐จ ๐ธ๐ช๐ต๐ฉ ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ฉ๐ข๐ด ๐ฃ๐ฆ๐ฆ๐ฏ ๐ฆ๐น๐ต๐ณ๐ฆ๐ฎ๐ฆ๐ญ๐บ ๐ฑ๐ฐ๐ด๐ช๐ต๐ช๐ท๐ฆ. ๐๐ฉ๐ฆ๐ช๐ณ ๐ด๐ต๐ณ๐ฆ๐ฏ๐จ๐ต๐ฉ ๐ช๐ฏ ๐ด๐บ๐ฏ๐ต๐ฉ๐ฆ๐ต๐ช๐ค ๐ค๐ฉ๐ฆ๐ฎ๐ช๐ด๐ต๐ณ๐บ, ๐ณ๐ฐ๐ถ๐ต๐ฆ ๐ด๐ค๐ฐ๐ถ๐ต๐ช๐ฏ๐จ, ๐ข๐ฏ๐ฅ ๐ฆ๐ง๐ง๐ช๐ค๐ช๐ฆ๐ฏ๐ต ๐ด๐ค๐ข๐ญ๐ฆ-๐ถ๐ฑ ๐ฉ๐ข๐ด ๐ข๐ญ๐ญ๐ฐ๐ธ๐ฆ๐ฅ ๐ถ๐ด ๐ต๐ฐ ๐ณ๐ข๐ฑ๐ช๐ฅ๐ญ๐บ ๐ข๐ค๐ค๐ฆ๐ด๐ด ๐ค๐ณ๐ช๐ต๐ช๐ค๐ข๐ญ ๐ฑ๐ณ๐ฆ๐ค๐ถ๐ณ๐ด๐ฐ๐ณ๐ด ๐ข๐ฏ๐ฅ ๐ง๐ช๐ฏ๐ข๐ญ ๐ค๐ฐ๐ฎ๐ฑ๐ฐ๐ถ๐ฏ๐ฅ๐ด ๐ข๐ต ๐ต๐ฉ๐ฆ ๐ฒ๐ถ๐ข๐ญ๐ช๐ต๐บ ๐ข๐ฏ๐ฅ ๐ฒ๐ถ๐ข๐ฏ๐ต๐ช๐ต๐ช๐ฆ๐ด ๐ณ๐ฆ๐ฒ๐ถ๐ช๐ณ๐ฆ๐ฅ ๐ง๐ฐ๐ณ ๐ฐ๐ถ๐ณ ๐ฑ๐ณ๐ฐ๐จ๐ณ๐ข๐ฎ. ๐๐ฉ๐ฆ ๐ต๐ฆ๐ข๐ฎ ๐ฉ๐ข๐ด ๐ค๐ฐ๐ฏ๐ด๐ช๐ด๐ต๐ฆ๐ฏ๐ต๐ญ๐บ ๐ฅ๐ฆ๐ญ๐ช๐ท๐ฆ๐ณ๐ฆ๐ฅ ๐ถ๐ฏ๐ฅ๐ฆ๐ณ ๐ต๐ช๐จ๐ฉ๐ต ๐ต๐ช๐ฎ๐ฆ๐ญ๐ช๐ฏ๐ฆ๐ด, ๐ธ๐ช๐ต๐ฉ ๐ฆ๐น๐ค๐ฆ๐ญ๐ญ๐ฆ๐ฏ๐ต ๐ฑ๐ณ๐ฐ๐ซ๐ฆ๐ค๐ต ๐ฎ๐ข๐ฏ๐ข๐จ๐ฆ๐ฎ๐ฆ๐ฏ๐ต ๐ข๐ฏ๐ฅ ๐ค๐ญ๐ฆ๐ข๐ณ ๐ค๐ฐ๐ฎ๐ฎ๐ถ๐ฏ๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ ๐ต๐ฉ๐ณ๐ฐ๐ถ๐จ๐ฉ๐ฐ๐ถ๐ต. ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ฉ๐ข๐ด ๐ฃ๐ฆ๐ฆ๐ฏ ๐ข ๐ฉ๐ช๐จ๐ฉ๐ญ๐บ ๐ณ๐ฆ๐ด๐ฑ๐ฐ๐ฏ๐ด๐ช๐ท๐ฆ ๐ข๐ฏ๐ฅ ๐ค๐ฐ๐ญ๐ญ๐ข๐ฃ๐ฐ๐ณ๐ข๐ต๐ช๐ท๐ฆ ๐ฑ๐ข๐ณ๐ต๐ฏ๐ฆ๐ณ, ๐ธ๐ช๐ต๐ฉ ๐ต๐ฉ๐ฆ ๐ข๐ฅ๐ฅ๐ฆ๐ฅ ๐ฃ๐ฆ๐ฏ๐ฆ๐ง๐ช๐ต ๐ฐ๐ง ๐ค๐ญ๐ฐ๐ด๐ฆ ๐ช๐ฏ๐ต๐ฆ๐ณ๐ข๐ค๐ต๐ช๐ฐ๐ฏ ๐ธ๐ช๐ต๐ฉ ๐ต๐ฉ๐ฆ๐ช๐ณ ๐ต๐ฆ๐ข๐ฎ๐ด ๐ช๐ฏ ๐๐บ๐ช๐ท ๐ข๐ฏ๐ฅ ๐๐ณ๐ข๐ฏ๐ฌ๐ง๐ถ๐ณ๐ต. ๐๐ท๐ฆ๐ณ๐ข๐ญ๐ญ, ๐ต๐ฉ๐ฆ ๐ฑ๐ณ๐ฐ๐ฅ๐ถ๐ค๐ต๐ช๐ท๐ช๐ต๐บ, ๐ณ๐ฆ๐ญ๐ช๐ข๐ฃ๐ช๐ญ๐ช๐ต๐บ, ๐ข๐ฏ๐ฅ ๐ฒ๐ถ๐ข๐ญ๐ช๐ต๐บ ๐ฐ๐ง ๐ฐ๐ถ๐ต๐ฑ๐ถ๐ต ๐ฉ๐ข๐ท๐ฆ ๐ฃ๐ฆ๐ฆ๐ฏ ๐ฐ๐ถ๐ต๐ด๐ต๐ข๐ฏ๐ฅ๐ช๐ฏ๐จ."
๐๐ฏ๐๐ง ๐๐๐ ๐ง๐๐ซ, ๐๐ก๐, ๐๐ข๐๐ ๐๐ซ๐๐ฌ๐ข๐๐๐ง๐ญ ๐จ๐ ๐๐๐ซ๐ญ๐ง๐๐ซ๐ฌ๐ก๐ข๐ฉ๐ฌ ๐๐ญ ๐๐ง๐๐ฆ๐ข๐ง๐: "๐๐ฆ ๐ข๐ณ๐ฆ ๐ท๐ฆ๐ณ๐บ ๐จ๐ญ๐ข๐ฅ ๐ต๐ฉ๐ข๐ต ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ฉ๐ข๐ด ๐ต๐ฉ๐ฆ ๐ฐ๐ฑ๐ฑ๐ฐ๐ณ๐ต๐ถ๐ฏ๐ช๐ต๐บ, ๐ธ๐ช๐ต๐ฉ ๐ช๐ต๐ด ๐ฌ๐ฏ๐ฐ๐ธ-๐ฉ๐ฐ๐ธ ๐ข๐ฏ๐ฅ ๐ฆ๐น๐ฆ๐ค๐ถ๐ต๐ช๐ฐ๐ฏ, ๐ต๐ฐ ๐ด๐ถ๐ฑ๐ฑ๐ฐ๐ณ๐ต ๐๐ถ๐ค๐ญ๐ช๐ฅ๐ฆ ๐๐ฉ๐ฆ๐ณ๐ข๐ฑ๐ฆ๐ถ๐ต๐ช๐ค๐ด, ๐ฎ๐ฆ๐ข๐ฏ๐ช๐ฏ๐จ๐ง๐ถ๐ญ ๐ข๐ฏ๐ฅ ๐ธ๐ช๐ต๐ฉ๐ฐ๐ถ๐ต ๐ฅ๐ฆ๐ญ๐ข๐บ, ๐ช๐ฏ ๐ต๐ฉ๐ฆ ๐ข๐ฅ๐ท๐ข๐ฏ๐ค๐ฆ๐ฎ๐ฆ๐ฏ๐ต ๐ฐ๐ง ๐ต๐ฉ๐ฆ๐ช๐ณ ๐ฑ๐ช๐ฐ๐ฏ๐ฆ๐ฆ๐ณ๐ช๐ฏ๐จ ๐ณ๐ข๐ฅ๐ช๐ฐ๐ต๐ฉ๐ฆ๐ณ๐ข๐ฏ๐ฐ๐ด๐ต๐ช๐ค ๐ฑ๐ณ๐ฐ๐จ๐ณ๐ข๐ฎ ๐ต๐ฐ๐ธ๐ข๐ณ๐ฅ๐ด ๐ง๐ช๐ณ๐ด๐ต-๐ช๐ฏ-๐ฉ๐ถ๐ฎ๐ข๐ฏ ๐ด๐ต๐ถ๐ฅ๐ช๐ฆ๐ด ๐ง๐ฐ๐ณ ๐ต๐ฉ๐ฆ ๐ต๐ณ๐ฆ๐ข๐ต๐ฎ๐ฆ๐ฏ๐ต ๐ฐ๐ง ๐ณ๐ฆ๐ด๐ช๐ด๐ต๐ข๐ฏ๐ต ๐ต๐ถ๐ฎ๐ฐ๐ถ๐ณ๐ด ๐ธ๐ฉ๐ฆ๐ณ๐ฆ ๐ฆ๐น๐ช๐ด๐ต๐ช๐ฏ๐จ ๐ค๐ข๐ฏ๐ค๐ฆ๐ณ ๐ต๐ฉ๐ฆ๐ณ๐ข๐ฑ๐ช๐ฆ๐ด ๐ฑ๐ณ๐ฐ๐ท๐ช๐ฅ๐ฆ ๐ฏ๐ฐ ๐ฎ๐ฆ๐ฅ๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ. ๐๐ฐ๐จ๐ฆ๐ต๐ฉ๐ฆ๐ณ, ๐ธ๐ฆ ๐ฉ๐ข๐ท๐ฆ ๐ฅ๐ฆ๐ฎ๐ฐ๐ฏ๐ด๐ต๐ณ๐ข๐ต๐ฆ๐ฅ ๐ข๐ฏ ๐ฆ๐น๐ค๐ฆ๐ฑ๐ต๐ช๐ฐ๐ฏ๐ข๐ญ๐ญ๐บ ๐ค๐ฐ๐ฐ๐ฑ๐ฆ๐ณ๐ข๐ต๐ช๐ท๐ฆ ๐ข๐ฏ๐ฅ ๐ข๐จ๐ช๐ญ๐ฆ ๐ต๐ฆ๐ข๐ฎ ๐ฐ๐ง ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ต๐ด ๐ด๐ถ๐ฑ๐ฑ๐ฐ๐ณ๐ต๐ช๐ฏ๐จ ๐ต๐ฉ๐ฆ ๐ฉ๐ช๐จ๐ฉ๐ญ๐บ ๐ฑ๐ข๐ต๐ช๐ฆ๐ฏ๐ต-๐ค๐ฆ๐ฏ๐ต๐ณ๐ช๐ค ๐ง๐ฐ๐ค๐ถ๐ด ๐ฐ๐ง ๐๐ถ๐ค๐ญ๐ช๐ฅ๐ฆ ๐๐ฉ๐ฆ๐ณ๐ข๐ฑ๐ฆ๐ถ๐ต๐ช๐ค๐ด. ๐๐ฉ๐ช๐ด ๐ด๐ถ๐ค๐ค๐ฆ๐ด๐ด๐ง๐ถ๐ญ ๐ค๐ฐ๐ฐ๐ฑ๐ฆ๐ณ๐ข๐ต๐ช๐ฐ๐ฏ ๐ฆ๐น๐ฆ๐ฎ๐ฑ๐ญ๐ช๐ง๐ช๐ฆ๐ด ๐ต๐ฉ๐ข๐ต ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ข๐ค๐ค๐ฆ๐ญ๐ฆ๐ณ๐ข๐ต๐ฆ๐ด ๐ต๐ฉ๐ฆ ๐ต๐ณ๐ข๐ฏ๐ด๐ช๐ต๐ช๐ฐ๐ฏ ๐ฐ๐ง ๐ด๐ฎ๐ข๐ญ๐ญ ๐ฎ๐ฐ๐ญ๐ฆ๐ค๐ถ๐ญ๐ฆ ๐ค๐ข๐ฏ๐ฅ๐ช๐ฅ๐ข๐ต๐ฆ๐ด ๐ช๐ฏ ๐ฑ๐ณ๐ฆ๐ค๐ญ๐ช๐ฏ๐ช๐ค๐ข๐ญ ๐ฅ๐ฆ๐ท๐ฆ๐ญ๐ฐ๐ฑ๐ฎ๐ฆ๐ฏ๐ต ๐ธ๐ช๐ต๐ฉ ๐ณ๐ข๐ฑ๐ช๐ฅ ๐ณ๐ฐ๐ถ๐ต๐ฆ ๐ด๐ค๐ฐ๐ถ๐ต๐ช๐ฏ๐จ ๐ข๐ฏ๐ฅ ๐ถ๐ฑ๐ด๐ค๐ข๐ญ๐ช๐ฏ๐จ ๐ข๐ต ๐ฅ๐ฆ๐ด๐ช๐ณ๐ฆ๐ฅ ๐ด๐ฑ๐ฆ๐ค๐ช๐ง๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ๐ด."
๐๐จ๐ฆ๐ฉ๐๐ง๐ฒ ๐๐ฎ๐ฆ๐ฆ๐๐ซ๐ข๐๐ฌ:
๐ผ๐๐ค๐ช๐ฉ ๐๐ช๐๐ก๐๐๐ ๐๐๐๐ง๐๐ฅ๐๐ช๐ฉ๐๐๐จ ๐๐ฉ๐.
Nuclide Therapeutics Ltd. is a pioneering clinical-stage biotech company and Kingโs College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers.
For more information, please visit: www.nuclidetx.com
๐ผ๐๐ค๐ช๐ฉ ๐๐ฃ๐๐ข๐๐ฃ๐
Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to the in-house produced screening compounds (4.7 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery.
For more information, please visit: https://enamine.net
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง
๐๐ค๐ง ๐๐ช๐๐ก๐๐๐ ๐๐๐๐ง๐๐ฅ๐๐ช๐ฉ๐๐๐จ:
Richard Edwards, PhD
Co-Founder & CTO
Email: rsedwards@nuclidetx.com
๐๐ค๐ง ๐๐ฃ๐๐ข๐๐ฃ๐:
Oleksii Gavrylenko
Director of Marketing
Email: o.gavrylenko@enamine.net
Oleksii Gavrylenko
Enamine Ltd
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
